KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBT Margin (2018 - 2025)

Vir Biotechnology's EBT Margin history spans 8 years, with the latest figure at 67.21% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 77872.0% to 67.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 638.56%, a 11380.0% increase, with the full-year FY2025 number at 638.56%, up 6639.0% from a year prior.
  • EBT Margin hit 67.21% in Q4 2025 for Vir Biotechnology, up from 67905.42% in the prior quarter.
  • Over the last five years, EBT Margin for VIR hit a ceiling of 106.9% in Q3 2021 and a floor of 67905.42% in Q3 2025.
  • Historically, EBT Margin has averaged 5856.14% across 5 years, with a median of 647.3% in 2022.
  • Biggest five-year swings in EBT Margin: skyrocketed 861301bps in 2022 and later plummeted -5893315bps in 2025.
  • Tracing VIR's EBT Margin over 5 years: stood at 67.17% in 2021, then crashed by -557bps to 306.9% in 2022, then crashed by -134bps to 719.35% in 2023, then decreased by -18bps to 845.93% in 2024, then surged by 92bps to 67.21% in 2025.
  • Business Quant data shows EBT Margin for VIR at 67.21% in Q4 2025, 67905.42% in Q3 2025, and 9125.86% in Q2 2025.